Access

Letter

Nature Chemical Biology 1, 371–376 (1 December 2005) | doi:10.1038/nchembio744

Monocarboxylate transporter MCT1 is a target for immunosuppression

Clare M Murray , Raymond Hutchinson , John R Bantick , Graham P Belfield , Amanda D Benjamin , Diana Brazma , Robert V Bundick , I David Cook , Robert I Craggs , Susan Edwards , Leslie R Evans , Richard Harrison , Elain Holness , Andrew P Jackson , Clive G Jackson , Lee P Kingston , Matthew W D Perry , Andrew R J Ross , Paul A Rugman , Sasvinder S Sidhu , Michael Sullivan , David A Taylor-Fishwick , P Craig Walker , Yvonne M Whitehead , David J Wilkinson , Andrew Wright & David K Donald

Current immunosuppressive therapies act on T lymphocytes by modulation of cytokine production, modulation of signaling pathways or by inhibition of the enzymes of nucleotide biosynthesis. We have identified a previously unknown series of immunomodulatory compounds that potently inhibit human and rat T lymphocyte proliferation in vitro and in vivo in immune-mediated animal models of disease, acting by a novel mechanism.